De novo and inherited TCF20 pathogenic variants are associated with intellectual disability, dysmorphic features, hypotonia, and neurological impairments with similarities to Smith-Magenis syndrome.
22q13
Deletions
Haploinsufficiency
Loss-of-function variants
Neurodevelopmental disorders
Smith–Magenis syndrome
TCF20
Journal
Genome medicine
ISSN: 1756-994X
Titre abrégé: Genome Med
Pays: England
ID NLM: 101475844
Informations de publication
Date de publication:
28 02 2019
28 02 2019
Historique:
received:
27
10
2018
accepted:
15
02
2019
entrez:
2
3
2019
pubmed:
2
3
2019
medline:
14
6
2019
Statut:
epublish
Résumé
Neurodevelopmental disorders are genetically and phenotypically heterogeneous encompassing developmental delay (DD), intellectual disability (ID), autism spectrum disorders (ASDs), structural brain abnormalities, and neurological manifestations with variants in a large number of genes (hundreds) associated. To date, a few de novo mutations potentially disrupting TCF20 function in patients with ID, ASD, and hypotonia have been reported. TCF20 encodes a transcriptional co-regulator structurally related to RAI1, the dosage-sensitive gene responsible for Smith-Magenis syndrome (deletion/haploinsufficiency) and Potocki-Lupski syndrome (duplication/triplosensitivity). Genome-wide analyses by exome sequencing (ES) and chromosomal microarray analysis (CMA) identified individuals with heterozygous, likely damaging, loss-of-function alleles in TCF20. We implemented further molecular and clinical analyses to determine the inheritance of the pathogenic variant alleles and studied the spectrum of phenotypes. We report 25 unique inactivating single nucleotide variants/indels (1 missense, 1 canonical splice-site variant, 18 frameshift, and 5 nonsense) and 4 deletions of TCF20. The pathogenic variants were detected in 32 patients and 4 affected parents from 31 unrelated families. Among cases with available parental samples, the variants were de novo in 20 instances and inherited from 4 symptomatic parents in 5, including in one set of monozygotic twins. Two pathogenic loss-of-function variants were recurrent in unrelated families. Patients presented with a phenotype characterized by developmental delay, intellectual disability, hypotonia, variable dysmorphic features, movement disorders, and sleep disturbances. TCF20 pathogenic variants are associated with a novel syndrome manifesting clinical characteristics similar to those observed in Smith-Magenis syndrome. Together with previously described cases, the clinical entity of TCF20-associated neurodevelopmental disorders (TAND) emerges from a genotype-driven perspective.
Sections du résumé
BACKGROUND
Neurodevelopmental disorders are genetically and phenotypically heterogeneous encompassing developmental delay (DD), intellectual disability (ID), autism spectrum disorders (ASDs), structural brain abnormalities, and neurological manifestations with variants in a large number of genes (hundreds) associated. To date, a few de novo mutations potentially disrupting TCF20 function in patients with ID, ASD, and hypotonia have been reported. TCF20 encodes a transcriptional co-regulator structurally related to RAI1, the dosage-sensitive gene responsible for Smith-Magenis syndrome (deletion/haploinsufficiency) and Potocki-Lupski syndrome (duplication/triplosensitivity).
METHODS
Genome-wide analyses by exome sequencing (ES) and chromosomal microarray analysis (CMA) identified individuals with heterozygous, likely damaging, loss-of-function alleles in TCF20. We implemented further molecular and clinical analyses to determine the inheritance of the pathogenic variant alleles and studied the spectrum of phenotypes.
RESULTS
We report 25 unique inactivating single nucleotide variants/indels (1 missense, 1 canonical splice-site variant, 18 frameshift, and 5 nonsense) and 4 deletions of TCF20. The pathogenic variants were detected in 32 patients and 4 affected parents from 31 unrelated families. Among cases with available parental samples, the variants were de novo in 20 instances and inherited from 4 symptomatic parents in 5, including in one set of monozygotic twins. Two pathogenic loss-of-function variants were recurrent in unrelated families. Patients presented with a phenotype characterized by developmental delay, intellectual disability, hypotonia, variable dysmorphic features, movement disorders, and sleep disturbances.
CONCLUSIONS
TCF20 pathogenic variants are associated with a novel syndrome manifesting clinical characteristics similar to those observed in Smith-Magenis syndrome. Together with previously described cases, the clinical entity of TCF20-associated neurodevelopmental disorders (TAND) emerges from a genotype-driven perspective.
Identifiants
pubmed: 30819258
doi: 10.1186/s13073-019-0623-0
pii: 10.1186/s13073-019-0623-0
pmc: PMC6393995
doi:
Substances chimiques
TCF20 protein, human
0
Transcription Factors
0
Types de publication
Case Reports
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
12Subventions
Organisme : NHGRI NIH HHS
ID : UM1HG006542
Pays : United States
Organisme : NINDS NIH HHS
ID : R35 NS105078-01
Pays : United States
Organisme : Department of Health
Pays : United Kingdom
Organisme : NINDS NIH HHS
ID : R35 NS105078
Pays : United States
Organisme : NHGRI NIH HHS
ID : K08 HG008986
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : WT098051
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_16018
Pays : United Kingdom
Organisme : NHGRI NIH HHS
ID : UM1 HG006542
Pays : United States
Commentaires et corrections
Type : ErratumIn
Type : CommentIn
Références
Am J Hum Genet. 2007 Apr;80(4):633-49
pubmed: 17357070
J Biol Chem. 2000 Aug 25;275(34):26144-9
pubmed: 10849425
Am J Hum Genet. 1991 Dec;49(6):1207-18
pubmed: 1746552
J Neurosci. 2011 Nov 9;31(45):16107-16
pubmed: 22072663
Eur J Hum Genet. 2014 Jan;22(1):79-87
pubmed: 23695279
Am J Med Genet A. 2014 Mar;164A(3):806-9
pubmed: 24375995
Am J Hum Genet. 2016 Feb 4;98(2):347-57
pubmed: 26805781
Eur J Med Genet. 2016 Sep;59(9):483-7
pubmed: 27452446
Genet Med. 2015 Jul;17(7):578-86
pubmed: 25356970
J Biol Chem. 2000 Dec 22;275(51):40288-300
pubmed: 10995766
J Clin Invest. 2006 Nov;116(11):3035-41
pubmed: 17024248
PLoS One. 2013 Oct 18;8(10):e78907
pubmed: 24205348
Genome Med. 2018 Sep 28;10(1):74
pubmed: 30266093
Nature. 2007 Jan 11;445(7124):168-76
pubmed: 17151600
Horm Behav. 2015 Jul;73:1-7
pubmed: 26012711
Pediatr Neurol. 2006 May;34(5):337-50
pubmed: 16647992
Hum Mol Genet. 2010 Oct 15;19(R2):R125-30
pubmed: 20805107
Am J Hum Genet. 2010 Mar 12;86(3):462-70
pubmed: 20188345
Genet Med. 2019 Mar;21(3):663-675
pubmed: 30158690
Genet Couns. 2004;15(3):347-55
pubmed: 15517828
Hum Mutat. 2010 Dec;31(12):1326-42
pubmed: 20848651
Genome Med. 2017 Sep 21;9(1):83
pubmed: 28934986
JAMA. 2014 Nov 12;312(18):1870-9
pubmed: 25326635
Nat Genet. 2003 Apr;33(4):466-8
pubmed: 12652298
N Engl J Med. 2017 Jan 5;376(1):21-31
pubmed: 27959697
PLoS One. 2014 Aug 15;9(8):e105077
pubmed: 25127133
PLoS One. 2011;6(9):e24659
pubmed: 21935435
Am J Hum Genet. 2011 Oct 7;89(4):580-8
pubmed: 21981782
Hum Genet. 2004 Nov;115(6):515-24
pubmed: 15565467
Nature. 2017 Feb 23;542(7642):433-438
pubmed: 28135719
Science. 2004 Dec 24;306(5705):2255-7
pubmed: 15618518
Dev Period Med. 2015 Apr-Jun;19(2):149-56
pubmed: 26384114
J Cell Physiol. 2016 Jul;231(7):1586-92
pubmed: 26566264
Eur J Hum Genet. 2016 Dec;24(12):1739-1745
pubmed: 27436265
PLoS One. 2012;7(9):e45155
pubmed: 23028815
Hum Mol Genet. 2010 Oct 15;19(20):4026-42
pubmed: 20663924
Eur J Hum Genet. 2008 Aug;16(8):941-54
pubmed: 18285828
Mol Cell Biol. 2005 May;25(9):3421-30
pubmed: 15831449
Mol Cell Biol. 1995 Jun;15(6):3164-70
pubmed: 7760812
Curr Genomics. 2010 Dec;11(8):607-17
pubmed: 21629438
Am J Med Genet A. 2009 Jul;149A(7):1382-91
pubmed: 19530184
J Pediatr. 2011 Apr;158(4):655-659.e2
pubmed: 21168152
J Med Genet. 2014 Nov;51(11):737-47
pubmed: 25228304
Neuroscience. 2013 Jun 3;239:295-303
pubmed: 23211562
PLoS Biol. 2010 Nov 23;8(11):e1000543
pubmed: 21124890
Nat Neurosci. 2016 Sep;19(9):1194-6
pubmed: 27479843
Hum Mol Genet. 2007 Aug 1;16(15):1802-13
pubmed: 17517686
PLoS One. 2011;6(8):e22861
pubmed: 21857958
Am J Med Genet A. 2016 Mar;170(3):792-4
pubmed: 26566763
Am J Hum Genet. 2018 Aug 2;103(2):171-187
pubmed: 30032986
J Med Genet. 2003 Aug;40(8):575-84
pubmed: 12920066
Biochem J. 2012 Feb 15;442(1):65-75
pubmed: 22081970
Eur J Hum Genet. 2018 Mar;26(3):293-302
pubmed: 29358616
J Med Genet. 2017 Apr;54(4):278-286
pubmed: 27799408
Eur J Hum Genet. 2014 Jun;22(6):844-6
pubmed: 24193349